Standout Papers

iRECIST: guidelines for response criter... 2004 2026 2011 2018 1.5k
  1. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics (2017)
    Lesley Seymour, Jan Bogaerts et al. The Lancet Oncology
  2. RECIST 1.1—Update and clarification: From the RECIST committee (2016)
    Lawrence H. Schwartz, Saskia Litière et al. European Journal of Cancer
  3. Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment (2019)
    Ana C. Garrido-Castro, Nancy U. Lin et al. Cancer Discovery
  4. CNS Metastases in Breast Cancer (2004)
    Nancy U. Lin, Jennifer R. Bellon et al. Journal of Clinical Oncology
  5. Sites of distant recurrence and clinical outcomes in patients with metastatic triple‐negative breast cancer (2008)
    Nancy U. Lin, Elizabeth B. Claus et al. Cancer
  6. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study (2017)
    Daniel Cagney, Allison Martin et al. Neuro-Oncology
  7. Clinicopathologic features, patterns of recurrence, and survival among women with triple‐negative breast cancer in the National Comprehensive Cancer Network (2012)
    Nancy U. Lin, Ann Vanderplas et al. Cancer
  8. Global challenges and policy solutions in breast cancer control (2022)
    Dario Trapani, Ophira Ginsburg et al. Cancer Treatment Reviews
  9. STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in BRCA1-deficient models of breast cancer (2022)
    Qiwei Wang, Johann S. Bergholz et al. Nature Communications
  10. Prognostic and Biologic Significance of ERBB2-Low Expression in Early-Stage Breast Cancer (2022)
    Paolo Tarantino, Qingchun Jin et al. JAMA Oncology
  11. Systemic Therapy for Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: ASCO Guideline Update (2022)
    Sharon H. Giordano, Maria Alice Franzoi et al. Journal of Clinical Oncology

Immediate Impact

4 by Nobel laureates 7 from Science/Nature 71 standout
Sub-graph 1 of 22

Citing Papers

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial
2023 Standout
Deciphering breast cancer: from biology to the clinic
2023 Standout
9 intermediate papers

Works of Nancy U. Lin being referenced

Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment
2019 Standout
Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update
2018
and 14 more

Author Peers

Author Last Decade Papers Cites
Nancy U. Lin 10838 7494 3908 368 16.5k
Aditya Bardia 10465 5194 4867 468 15.3k
Véronique Dièras 17949 9207 6141 351 22.5k
Angelo Di Leo 9688 4372 5062 309 14.0k
Sara M. Tolaney 11070 5064 3587 487 14.1k
Igor Bondarenko 12964 8783 3459 303 17.1k
John Crown 12728 4664 5824 413 19.6k
Jungsil Ro 7720 5123 3610 190 13.1k
Hiroji Iwata 16179 9284 6860 514 22.9k
Mario Campone 14956 8736 6936 532 23.2k
Ian E. Krop 13507 5250 3879 296 18.4k

All Works

Loading papers...

Rankless by CCL
2026